[Pubmed] Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature r
Posté : 17 févr. 2025 12:00
Front Neurol. 2025 Jan 31;16:1501500. doi: 10.3389/fneur.2025.1501500. eCollection 2025.
ABSTRACT
BACKGROUND: Despite existing treatments of generalized myasthenia gravis (gMG), there remains a need for more effective therapies with fewer side effects. Telitacicept, targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), emerges as a potential novel therapy for gMG.
CASE PRESENTATION: In our study, four patients with gMG to standard treatments underwent an 8-week course of telitacicept monotherapy. Post-treatment, all patients exhibited satisfactory improvements. The Myasthenia Gravis Foundation of America Quantitative Myasthenia Gravis (MGFA-QMG) scores, 15-item Myasthenia Gravis Quality of Life (MGQOL-15) scores, and MG-associated Activities of Daily Living (MG-ADL) scores showed a marked reduction, indicating decreased disease severity and enhanced quality of life. Additionally, immunological assessments revealed a decrease in CD19+B lymphocyte counts and acetylcholine receptor (AChR) antibodies. Only one patient reported a mild, transient injection reaction.
CONCLUSION: Favorable clinical improvement and mild adverse events for gMG in treated with telitacicept were observed. However, larger-scale and longer-term studies are necessary to confirm these results and fully establish the role of telitacicept in the treatment of gMG.
PMID:39958611 | PMC:PMC11825329 | DOI:10.3389/fneur.2025.1501500
Source: https://pubmed.ncbi.nlm.nih.gov/3995861 ... t9+e462414